908 Devices Inc. develops and manufactures purpose-built handheld devices for point-of-need chemical analysis, leveraging mass spectrometry, optical spectroscopy, and machine learning technologies. The company’s product portfolio includes the MX908, ThreatID, ProtectIR, XplorIR, and VipIR, which are designed to detect and identify unknown materials in health, safety, and defense applications, including the detection of fentanyl, illicit drugs, and toxic carcinogens. The company utilizes a proprietary High-Pressure Mass Spec (HPMS) platform that miniaturizes ion traps and vacuum systems to enable portable, low-power operation. In April 2024, the company acquired CAM2 Technologies, LLC, doing business as RedWave Technology, to integrate vibrational spectroscopy capabilities. Customers include domestic and foreign government agencies, such as the U.S. Department of Homeland Security, the U.S. Army, and the U.S. Air Force, as well as other federal and state entities. The business model involves the sale of devices, consumables, accessories, and support services.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Scientific & Technical Instruments Homepage 908devices.com
Sector Technology IR page ir.908devices.com
Tags
mass spectrometry, optical spectroscopy, handheld devices, chemical analysis, drug detection, defense technology, point-of-care testing, machine learning, microfabrication, MX908, ThreatID, ProtectIR, XplorIR, VipIR, CAM2 Technologies LLC, RedWave Technology
Press page —

Metrics

Valuation  
Market cap $ 453.538M
Market cap (USD) $ 453.538M
P/E -16.70
PEG —
P/BV 3.03
P/S 6.89
P/OCF 157.26
P/FCF 172.91
Dividend yield —
Turnover / mcap —
Returns  
ROE 15.1%
ROI 25.3%
ROIC -38.3%
Profit margin 34.7%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 18
Quality score -17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 56.197M 59.631M 50.229M 46.852M 42.206M 26.894M
Net profit 19.489M -72.206M -36.399M -33.563M -22.169M -12.819M
Free cash flow -24.643M -30.849M -27.104M -22.975M -29.819M 4.122M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 5.25 2.2 11.22 7.62 25.87 56.95
Price performance 12m 1.39 -0.8 0.47 -0.71 -0.55 —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 6.83M 16.4M 10M 8.99M 12.6M 11.3M
↳ YoY growth +139.9% -38.7% -10.4% +40.5% -10.3%
↳ 5y CAGR +10.7%
Borrowings, current (USD) — 500,000 — — — — —
Borrowings, non-current (USD) — 14.3M 15M 15M — — —
Lease liabilities (USD) — 7.03M 5.85M 4.51M 5.95M 6.61M 4.63M
Cash and deposits (USD) 17.9M 159M 224M 188M 121M 44M 70.5M
Intangible assets (USD) — — — 8.49M 7.86M 45.3M 36.4M
Right-of-use assets (USD) — 6.29M 5.18M 3.96M 6.23M 6.91M 4.4M
Net debt (borrowings + leases - cash) (USD) — -137M -203M -169M — — —
Cash flow detail
Operating cash flow (USD) — 4.13M -29.1M -20.9M -25.1M -30.2M -23.7M
Purchases of property, plant and equipment (USD) — -9,000 -737,000 -2.05M -2.05M -602,000 -955,000
Change in receivables (cash effect) (USD) — -1.82M -11.3M 5.93M 680,000 -2.93M 220,000
Change in inventories (cash effect) (USD) — 223,000 -4.48M -5.48M -3.9M -1.66M -3.73M
Change in payables (cash effect) (USD) — 1.98M 2.75M 452,000 2.03M 2.32M -5.93M
Interest paid (cash effect) (USD) — -913,000 -366,000 -135,000 — — —
Income taxes paid (cash effect) (USD) — — — — — -184,000 66,000
Share-based compensation (USD) — 525,000 2.5M 7.21M 9.79M 11.8M 9.85M
Operating cash flow before change in receivables (USD) — 5.95M -17.8M -26.9M -25.7M -27.3M -23.9M
Free cash flow (OCF - PPE - intangibles) (USD) — 4.12M -29.8M -23M -27.1M -30.8M -24.6M
Income detail
Research and development expense (USD) — 8.24M 13.1M 17.5M 21.9M 25.5M 15.6M
↳ 5y CAGR +13.6%
Total comprehensive income (USD) — — -22.2M -32.8M -35.8M -72.4M 18.4M
Comprehensive income to owners (USD) — — -22.2M -32.8M -35.8M -72.4M 18.4M
Provision for credit losses (USD) — 100,000 1.73M — 386,000 190,000 —
Credit cost ratio (credit losses / average receivables) (%) — — 14.9% — 4.1% 1.8% —
Reported May 13, 2021 Mar 11, 2022 Mar 15, 2023 Mar 15, 2023 Mar 8, 2024 Mar 7, 2025 Mar 9, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Revenue increased 35% compared to prior year

Raises low end of 2026 revenue outlook

BURLINGTON, Mass. – November 10, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended September 30, 2026.

"We had a strong third quarter, driven by our FTIR portfolio, with revenue growing 35% year-over-year to $19 million and device shipments reaching a new company record,” said Kevin J. Knopp, CEO and Co-founder. "Our proven platforms are winning orders across the globe as customers accelerate efforts to modernize their detection capabilities and stay ahead of an evolving threat landscape. NIRLab is also gaining traction, both in unit volumes and pipeline, as we build a growing base of connected, recurring revenue.

10/27/2026

Download(opens in new window)PDF 94 KB

BURLINGTON, Mass.--(BUSINESS WIRE)-- 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the third quarter 2026 before market open on Tuesday, November 10, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.908devices.com . The webcast will be archived and available for replay within 24 hours after the event.

**About 908 Devices
**908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com .

Matt Roache
VP, Investor Relations
[email protected]

www.908devices.com

Source: 908 Devices Inc.

Multimedia Files:

Company's logo

Company's logo 4743 x 1356 jpg 553 KB

Download:

Download original jpg 553 KB 4743 x 1356

Download thumbnail png 7 KB 200 x 57

Download lowres png 19 KB 480 x 137

Download square png 9 KB 250 x 250

View all news

Prompts

908 Devices Inc. (ticker MASS), listed in United States.

ETFs Holding 908 Devices Inc.

ETF Weight in ETF Shares Market value As of
ARKG 1.09% 2,120,183 $ 19.909M Nov 18, 2026
AVUV 0.04% 1,234,336 $ 11.344M Nov 16, 2026
AVSC 0.02% 66,934 $ 615.123K Nov 16, 2026
DFSU 0.00% 4,574 $ 44.779K Nov 12, 2026
DFAS 0.00% 53,361 $ 522.404K Nov 12, 2026
DFAU 0.00% 12,435 $ 121.739K Nov 12, 2026
DFUS 0.00% 6,775 $ 66.327K Nov 12, 2026
DXUV 0.00% 1,176 $ 11.513K Nov 12, 2026
DCOR 0.00% 4,484 $ 43.898K Nov 12, 2026
DFAC 0.00% 7,722 $ 75.598K Nov 12, 2026
AVUS 0.00% 20,670 $ 189.957K Nov 16, 2026
AVSU 0.00% 205 $ 1,883.95 Nov 16, 2026